Literature DB >> 17214372

Diagnostic relevance of overexpressed NOK mRNA in breast cancer.

Ryosuke Moriai1, Daisuke Kobayashi, Tomoko Amachika, Naoki Tsuji, Naoki Watanabe.   

Abstract

A novel oncogene with a kinase domain (NOK), a receptor protein tyrosine kinase, has been reported to cause proliferation of normal cells, suggesting its possible use as a diagnostic marker in human cancer. To determine the significance of NOK expression in cancer cells, the effect of NOK inhibition was first examined on cell proliferation in vitro. The degree of expression in 52 clinical breast cancer samples was then correlated with clinical features. The transduction of NOK small inhibitory (si) RNA in T47D breast cancer cells decreased NOK mRNA expression, thereby inhibiting growth. When the mean expression in non-cancerous tissues from the same breast resection specimens +/-2SD was used as a cut-off value, 67.3% of breast cancers were positive for NOK expression - a higher positivity rate than that found for c-erbB2 (28.8%). NOK mRNA expression did not correlate with c-erbB2 expression, indicating the independence of NOK as a diagnostic marker. Furthermore, NOK mRNA was highly expressed even at early clinical stages. NOK mRNA might be an ideal target to support the diagnosis of breast cancer especially in tiny tumors in which the malignancy cannot be confirmed by other means.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214372

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma.

Authors:  Yanhong Liu; Beatrice S Melin; Preetha Rajaraman; Zhaoming Wang; Martha Linet; Sanjay Shete; Christopher I Amos; Ching C Lau; Michael E Scheurer; Spiridon Tsavachidis; Georgina N Armstrong; Richard S Houlston; Fay J Hosking; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Joellen Schildkraut; Siegal Sadetzki; Christoffer Johansen; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Daniel LaChance; Nicholas A Vick; Margaret Wrensch; Faith Davis; Bridget J McCarthy; Ulrika Andersson; Patricia A Thompson; Stephen Chanock; Melissa L Bondy
Journal:  Hum Genet       Date:  2012-06-12       Impact factor: 4.132

2.  Aberrantly High Expression Of NOK/STYK1 Is Tightly Associated With The Activation Of The AKT/GSK3β/N-Cadherin Pathway In Non-Small Cell Lung Cancer.

Authors:  Zhao Huang; Nan Ma; Yan-Lu Xiong; Lei Wang; Wei-Miao Li; Yuan-Yang Lai; Chen-Xi Zhang; Zhi-Pei Zhang; Xiao-Fei Li; Jin-Bo Zhao
Journal:  Onco Targets Ther       Date:  2019-11-27       Impact factor: 4.147

3.  Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer.

Authors:  Liang Hu; Hai-Yang Chen; Jian Cai; Yu Zhang; Chen-Ye Qi; Hui Gong; Yan-Xia Zhai; Hao Fu; Guang-Zhen Yang; Chun-Fang Gao
Journal:  BMC Cancer       Date:  2015-04-10       Impact factor: 4.430

4.  Identification of six polymorphisms as novel susceptibility loci for ischemic or hemorrhagic stroke by exome-wide association studies.

Authors:  Yoshiji Yamada; Jun Sakuma; Ichiro Takeuchi; Yoshiki Yasukochi; Kimihiko Kato; Mitsutoshi Oguri; Tetsuo Fujimaki; Hideki Horibe; Masaaki Muramatsu; Motoji Sawabe; Yoshinori Fujiwara; Yu Taniguchi; Shuichi Obuchi; Hisashi Kawai; Shoji Shinkai; Seijiro Mori; Tomio Arai; Masashi Tanaka
Journal:  Int J Mol Med       Date:  2017-05-03       Impact factor: 4.101

5.  STYK1 promotes tumor growth and metastasis by reducing SPINT2/HAI-2 expression in non-small cell lung cancer.

Authors:  Zhiqiang Ma; Dong Liu; Weimiao Li; Shouyin Di; Zhipei Zhang; Jiao Zhang; Liqun Xu; Kai Guo; Yifang Zhu; Jing Han; Xiaofei Li; Xiaolong Yan
Journal:  Cell Death Dis       Date:  2019-06-04       Impact factor: 8.469

6.  Aberrant STYK1 expression in ovarian cancer tissues and cell lines.

Authors:  Kesmic A Jackson; Gabriela Oprea; Jeffrey Handy; K Sean Kimbro
Journal:  J Ovarian Res       Date:  2009-10-21       Impact factor: 4.234

7.  STYK1/NOK Promotes Metastasis and Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer by Suppressing FoxO1 Signaling.

Authors:  Yuanyang Lai; Fang Lin; Xuejiao Wang; Jiao Zhang; Jinghua Xia; Ying Sun; Miaomiao Wen; Xiaofei Li; Zhipei Zhang; Jinbo Zhao
Journal:  Front Cell Dev Biol       Date:  2021-07-06

8.  Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer.

Authors:  Peng Chen; Wei-Miao Li; Qiang Lu; Jian Wang; Xiao-Long Yan; Zhi-Pei Zhang; Xiao-Fei Li
Journal:  BMC Cancer       Date:  2014-06-04       Impact factor: 4.430

9.  STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.

Authors:  Zhaowen Wang; Lei Qu; Biao Deng; Xing Sun; Shaohan Wu; Jianhua Liao; Junwei Fan; Zhihai Peng
Journal:  Sci Rep       Date:  2016-09-15       Impact factor: 4.379

10.  Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients.

Authors:  Luguang Chen; Chao Ma; Yun Bian; Chengwei Shao; Tiegong Wang; Jing Li; Xiaodan Chong; Li Su; Jianping Lu
Journal:  Oncotarget       Date:  2017-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.